Pharmaceuticals - Indian - Formulations
Particulars (in ₹ Cr.) | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|
Total Revenue | 192.42 | 171.04 | 144.67 | 141.92 | 147.72 |
Total Expenses | 159.74 | 146.90 | 125.29 | 126.44 | 131.60 |
Profit Before Tax | 32.45 | 24.15 | 19.38 | 15.47 | 15.79 |
Profit After Tax | 20.58 | 14.90 | 12.44 | 10.12 | 9.64 |
Operating Profit after Depreciation | 33.12 | 24.86 | 21.15 | 17.95 | 19.24 |
Particulars (in ₹ Cr.) | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|
Fixed Assets | 28.91 | 24.09 | 26.76 | 30.06 | 32.85 |
Total Non Current Assets | 39.95 | 41.06 | 42.02 | 60.78 | 63.54 |
Total Current Assets | 100.49 | 82.84 | 78.25 | 63.38 | 60.67 |
TOTAL ASSETS | 140.44 | 123.90 | 120.27 | 124.16 | 124.21 |
Total Shareholder's Fund | 108.74 | 94.95 | 89.24 | 82.27 | 77.27 |
Particulars (in ₹ Cr.) | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 20.70 | 18.32 | 17.45 | 8.62 | 3.62 |
Net Cash used in Investing Activities | 4.16 | -4.89 | 16.49 | 13.49 | 14.50 |
Net Cash used in Financing Activities | -13.10 | -11.93 | -13.92 | -14.26 | -27.31 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 437.58 | 394.18 | 421.22 | 344.16 | 269.80 |
Total Expenses | 375.63 | 340.53 | 330.65 | 262.26 | 235.34 |
Profit Before Tax | 61.95 | 53.65 | 90.58 | 81.90 | 34.45 |
Profit After Tax | 44.97 | 39.83 | 67.19 | 61.19 | 25.08 |
Operating Profit after Depreciation | 62.10 | 53.72 | 91.06 | 82.40 | 34.67 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 49.58 | 48.91 | 29.52 | 24.42 | 26.10 |
Total Non Current Assets | 71.19 | 102.15 | 75.22 | 51.37 | 79.52 |
Total Current Assets | 295.68 | 259.95 | 274.65 | 222.90 | 125.82 |
TOTAL ASSETS | 366.87 | 362.09 | 349.87 | 274.27 | 205.35 |
Total Shareholder's Fund | 288.49 | 290.77 | 265.12 | 215.56 | 159.43 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 27.91 | 20.18 | 52.20 | 90.87 | 18.18 |
Net Cash used in Investing Activities | 19.17 | -2.48 | -36.21 | -87.76 | -13.85 |
Net Cash used in Financing Activities | -48.27 | -14.99 | -16.70 | -7.42 | -11.69 |
No data available
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 109.92 | 83.74 | 127.06 | 116.99 | 99.31 |
Total Expenses | 96.32 | 80.18 | 110.83 | 95.42 | 92.47 |
Profit Before Tax | 15.94 | 6.36 | 19.60 | 23.70 | 9.21 |
Profit After Tax | 11.80 | 4.62 | 13.66 | 17.45 | 6.85 |
Operating Profit after Depreciation | 17.65 | 8.01 | 21.18 | 25.33 | 10.79 |
₹1/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Amrutanjan Health Care Ltd | ₹665.85 | ₹1,925.01 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
13 Nov 2024, 09:51 am
05 Nov 2024, 11:59 am
02 Sep 2024, 09:37 am
07 Aug 2024, 12:33 pm
24 May 2024, 09:25 am